Nektar Management to Present at Upcoming Investor Conferences
Get Alerts NKTR Hot Sheet
Join SI Premium – FREE
H.C. Wainwright 26th Annual Global Investment Conference inNew York City onMonday, September 9, 2024 at3:00 p.m. Eastern Time /12:00 p.m. Pacific Time - Stifel Virtual Immunology and Inflammation Summit on
Tuesday, September 17, 2024 at12:30 p.m. Eastern Time /9:30 a.m. Pacific Time
The presentations will be accessible via webcast through links posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. The webcasts will be available for replay until
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.
Contact:
For Investors:
628-895-0661
For Media:
(212) 600-1902
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-management-to-present-at-upcoming-investor-conferences-302236329.html
SOURCE Nektar Therapeutics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jeff Weniger joins Corgi as Chief Investment Strategist After Nearly a Decade at WisdomTree Asset Management
- SerpApi Surpasses 1.5 Million Activated User Accounts, Empowering Developers Everywhere with Structured Access to the World's Search Data
- Castelion Raises $1 Billion Series C to Scale Production of Low-Cost Hypersonic Weapons
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share